for eMaxHealthCarcinoid Cancer
Callisto Pharmaceuticals announced the addition of a clinical site to its Phase II clinical trial of Atiprimod to treat low to intermediate grade neuroendocrine carcinoma (advanced carcinoid cancer).
The additional site is the Scott & White Memorial Hospital, Scott Sherwood and Brindley Foundation, 2401 South 31st Street, Temple, TX 76508. The principal investigator for the Scott & White Memorial Hospital is Arthur Frankel, M.D.
"The addition of this major cancer center to the Phase II trial of Atiprimod in advanced carcinoid patients signifies our continuing commitment to facilitate rapid enrollment of this trial," said Dr. Gary S. Jacob, Chief Executive Officer of Callisto. "This site is active in the treatment of neuroendocrine cancers, which should substantially enhance the pace of enrollment and increased accessibility to prospective patients interested in participating in this trial." Currently Callisto has enrolled 23 patients of the 40 subjects planned for this Phase II clinical trial.
eMaxHealth welcomes yourcomments and feedback on this story without registration, but keep the comments meaningful please. Links are not accepted.
